|
Active substance |
Hemlibra |
|
Holder |
NV Roche SA |
|
Status |
Closed |
|
Indication |
Routine prophylaxis of bleeding episodes in patients with severe haemophilia A without factor VIII inhibitors and with inadequate response on their current treatment. |
|
Public documents |
|
|
Last update |
05/03/2020 |
Hemlibra
Last updated on 03/04/2024